Jasper Therapeutics Unveils Plans for Public Offering of Common Stock and Warrants
Public Offering Announcement: Jasper Therapeutics, Inc. has announced plans for an underwritten public offering of its common stock, with options for certain investors to purchase pre-funded warrants alongside common warrants.
Use of Proceeds: The company aims to use the net proceeds from the offering to further its preclinical and clinical development programs for briquilimab, as well as for general corporate purposes including capital expenditures and working capital.
Trade with 70% Backtested Accuracy
Analyst Views on JSPR
About JSPR
About the author
Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
Jasper Stock Soars Following Positive Results from New Asthma Study
Briquilimab Study Results: Jasper Therapeutics released preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced sputum eosinophils and improved lung function indicators in adults with allergic asthma, demonstrating a favorable safety profile.
Eosinophil Reduction: Treatment with briquilimab led to substantial decreases in sputum eosinophil levels before and after allergen challenges, indicating its potential effectiveness in managing allergic asthma symptoms.
BEACON Cohort Investigation: Jasper completed an internal investigation into the lack of clinical response in the BEACON study cohorts, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug itself.
Stock Performance: Following the positive study results, Jasper Therapeutics' shares increased by 8.72%, reaching $1.87 at the time of publication.
Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement
- Positive Clinical Data: The ETESIAN study revealed that a single 180mg dose of briquilimab significantly reduced airway hyperresponsiveness and eosinophil levels at both 6 and 12 weeks, indicating its potential in asthma treatment.
- Favorable Safety Profile: Briquilimab demonstrated good tolerability in the study, with no dose-limiting toxicities observed, enhancing its appeal as a new therapeutic option.
- Resolution of Patient Selection Issues: Jasper concluded its internal investigation into the lack of clinical response in the BEACON study, confirming that the issue stemmed from patient selection rather than drug product, ensuring the validity of future studies.
- Promising Future Development: Jasper plans to initiate a Phase 2b study for chronic spontaneous urticaria in mid-2026, leveraging the positive outcomes from the ETESIAN study to further advance briquilimab's development.
Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement
- Clinical Trial Success: The ETESIAN study demonstrated that a single 180mg dose of Briquilimab significantly reduced airway hyperresponsiveness and sputum eosinophils at both 6 and 12 weeks, indicating its potential in asthma treatment.
- Impressive Efficacy Data: Briquilimab showed improvements in Late Asthmatic Response with FEV1 enhancements of 10.4% at 6 weeks and 8.7% at 12 weeks, highlighting its effectiveness in improving respiratory function in asthma patients.
- Good Safety Profile: The drug exhibited favorable tolerability with no dose-limiting toxicities observed, further enhancing its credibility as a new treatment option for asthma.
- Future Research Plans: Jasper intends to initiate a Phase 2b study in mid-2026 to further validate Briquilimab's efficacy in chronic urticaria patients, demonstrating the company's confidence in the drug's future development.
Jasper Therapeutics Announces Encouraging Findings for Briquilimab in Phase 1b Study of Allergic Asthma
Study Overview: Jasper Therapeutics reported positive preliminary data from its ETESIAN Phase 1b study of briquilimab for allergic asthma, showing significant reductions in sputum eosinophils and improvements in lung function.
Efficacy Results: A single dose of briquilimab resulted in notable improvements in FEV1 during both Early and Late Asthmatic Responses, along with significant reductions in serum tryptase levels.
Safety Profile: The treatment was well tolerated, indicating a favorable safety profile for briquilimab in the study participants.
Future Development: The encouraging results support the ongoing development of briquilimab as a potential new treatment option for asthma.
Jasper Therapeutics to Hold Webinar Showcasing Results from BEACON and ETESIAN Studies
Jasper Therapeutics Webinar: Jasper Therapeutics Inc. will host a webinar on December 2, 2025, to present findings from its BEACON study on chronic spontaneous urticaria and preliminary data from the ETESIAN study on asthma.
BEACON Study Results: The BEACON trial, which evaluates Briquilimab for chronic spontaneous urticaria, reported that 89% of participants achieved a complete response with certain doses, and 73% maintained this response in an open-label extension.
ETESIAN Study Status: The ETESIAN study, focused on allergic asthma, was halted earlier this year due to a drug product lot issue, pausing further development in asthma.
Stock Performance: Jasper Therapeutics' stock closed at $1.72, down 6.52%, but saw a 16.27% increase in overnight trading, reaching $2 on the Nasdaq.
Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
Jasper Stock Soars Following Positive Results from New Asthma Study
Briquilimab Study Results: Jasper Therapeutics released preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced sputum eosinophils and improved lung function indicators in adults with allergic asthma, demonstrating a favorable safety profile.
Eosinophil Reduction: Treatment with briquilimab led to substantial decreases in sputum eosinophil levels before and after allergen challenges, indicating its potential effectiveness in managing allergic asthma symptoms.
BEACON Cohort Investigation: Jasper completed an internal investigation into the lack of clinical response in the BEACON study cohorts, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug itself.
Stock Performance: Following the positive study results, Jasper Therapeutics' shares increased by 8.72%, reaching $1.87 at the time of publication.
Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement
- Positive Clinical Data: The ETESIAN study revealed that a single 180mg dose of briquilimab significantly reduced airway hyperresponsiveness and eosinophil levels at both 6 and 12 weeks, indicating its potential in asthma treatment.
- Favorable Safety Profile: Briquilimab demonstrated good tolerability in the study, with no dose-limiting toxicities observed, enhancing its appeal as a new therapeutic option.
- Resolution of Patient Selection Issues: Jasper concluded its internal investigation into the lack of clinical response in the BEACON study, confirming that the issue stemmed from patient selection rather than drug product, ensuring the validity of future studies.
- Promising Future Development: Jasper plans to initiate a Phase 2b study for chronic spontaneous urticaria in mid-2026, leveraging the positive outcomes from the ETESIAN study to further advance briquilimab's development.
Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement
- Clinical Trial Success: The ETESIAN study demonstrated that a single 180mg dose of Briquilimab significantly reduced airway hyperresponsiveness and sputum eosinophils at both 6 and 12 weeks, indicating its potential in asthma treatment.
- Impressive Efficacy Data: Briquilimab showed improvements in Late Asthmatic Response with FEV1 enhancements of 10.4% at 6 weeks and 8.7% at 12 weeks, highlighting its effectiveness in improving respiratory function in asthma patients.
- Good Safety Profile: The drug exhibited favorable tolerability with no dose-limiting toxicities observed, further enhancing its credibility as a new treatment option for asthma.
- Future Research Plans: Jasper intends to initiate a Phase 2b study in mid-2026 to further validate Briquilimab's efficacy in chronic urticaria patients, demonstrating the company's confidence in the drug's future development.
Jasper Therapeutics Announces Encouraging Findings for Briquilimab in Phase 1b Study of Allergic Asthma
Study Overview: Jasper Therapeutics reported positive preliminary data from its ETESIAN Phase 1b study of briquilimab for allergic asthma, showing significant reductions in sputum eosinophils and improvements in lung function.
Efficacy Results: A single dose of briquilimab resulted in notable improvements in FEV1 during both Early and Late Asthmatic Responses, along with significant reductions in serum tryptase levels.
Safety Profile: The treatment was well tolerated, indicating a favorable safety profile for briquilimab in the study participants.
Future Development: The encouraging results support the ongoing development of briquilimab as a potential new treatment option for asthma.
Jasper Therapeutics to Hold Webinar Showcasing Results from BEACON and ETESIAN Studies
Jasper Therapeutics Webinar: Jasper Therapeutics Inc. will host a webinar on December 2, 2025, to present findings from its BEACON study on chronic spontaneous urticaria and preliminary data from the ETESIAN study on asthma.
BEACON Study Results: The BEACON trial, which evaluates Briquilimab for chronic spontaneous urticaria, reported that 89% of participants achieved a complete response with certain doses, and 73% maintained this response in an open-label extension.
ETESIAN Study Status: The ETESIAN study, focused on allergic asthma, was halted earlier this year due to a drug product lot issue, pausing further development in asthma.
Stock Performance: Jasper Therapeutics' stock closed at $1.72, down 6.52%, but saw a 16.27% increase in overnight trading, reaching $2 on the Nasdaq.
